Resveratrol alleviates vascular inflammatory injury by inhibiting inflammasome activation in rats with hypercholesterolemia and vitamin D2 treatment

Inflammation Research

Volumn 64, Issue 5, 2015, Pages 321-332

  Deng, Zu Yue ^a,b   Hu, Meng Mei ^a,b   Xin, Yan Fei ^c   Gang, Chen ^c  

^a ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^b Zhejiang Institute for Food and Drug Control   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Hypercholesterolemia; NLRP3 inflammasome; Resveratrol; Vascular injury

Indexed keywords

ANTIOXIDANT; CARRIER PROTEIN; ERGOCALCIFEROL; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPID; NOD-LIKE RECEPTOR 3, RAT; NONSTEROID ANTIINFLAMMATORY AGENT; RESVERATROL; STILBENE DERIVATIVE; VITAMIN;

ANIMAL; ATHEROSCLEROSIS; BLOOD; COMPLICATION; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPID PEROXIDATION; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; THORACIC AORTA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; AORTA, THORACIC; ATHEROSCLEROSIS; CARRIER PROTEINS; CASPASE 1; ERGOCALCIFEROLS; HYPERCHOLESTEROLEMIA; INFLAMMASOMES; INFLAMMATION; LIPID PEROXIDATION; LIPIDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; VITAMINS;

EID: 84937762684     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-015-0810-4     Document Type: Article

References (34)

1. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med. 1976;295:369–77.
2. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Eng J Med. 1976;295:420–5.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–9.
4. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211–7.
5. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138:S419–20.
6. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417–26.
7. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20:319–25.
8. Zheng X, Zhu S, Chang S, et al. Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: role of NF-kappa B signaling. Eur J Pharmacol. 2013;720:147–57.
9. Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol. 2011;166:1–15.
10. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science (NY). 2010;327:296–300.
11. De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011;32:373–9.
12. Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biol Pharm Bull. 2012;35:273–9.
13. Dong W, Wang X, Bi S, et al. Inhibitory effects of resveratrol on foam cell formation are mediated through monocyte chemotactic protein-1 and lipid metabolism-related proteins. Int J Mol Med. 2014;33(5):1161–8.
14. Huang TT, Lai HC, Chen YB, et al. cis-Resveratrol produces anti-inflammatory effects by inhibiting canonical and non-canonical inflammasomes in macrophages. Innate immun. 2013;20(7):735–50.
15. Fu Y, Wang Y, Du L, et al. Resveratrol inhibits ionising irradiation-induced inflammation in MSCs by activating SIRT1 and limiting NLRP-3 inflammasome activation. Int J Mol Sci. 2013;14:14105–18.
16. Bennani-Kabchi N, Kehel L, el Bouayadi F, et al. New model of atherosclerosis in sand rats subjected to a high cholesterol diet and vitamin D2. Therapie. 1999;54:559–65.
17. Wen C, Yang X, Yan Z, et al. Nalp3 inflammasome is activated and required for vascular smooth muscle cell calcification. Int J Cardiol. 2013;168(3):2242–7.
18. Tang FT, Chen SRWu, Q X, et al. Hypercholesterolemia accelerates vascular calcification induced by excessive vitamin D via oxidative stress. Calcif Tissue Int. 2006;79(5):326–39.
19. Jiang HH, Liu Y, Lin GQ, Li YQ, xue xue bao Zhong nan da, xue ban Yi. Change of vWF, PAl-1 and t-PA in rats with hyperlipemia and its significance. Medical sciences. J Cent South Univ. 2008;n33:415–20.
20. Luo B, Li B, Wang W, et al. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3. Inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther/Spons Int Soc Cardiovasc Pharmacother. 2014;28:33–43.
21. Weber A, Wasiliew P, Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci Signal. 2010;3:105 (cm2).
22. Annabi B, Lord-Dufour S, Vezina A, Beliveau R. Resveratrol targeting of carcinogen-induced brain endothelial cell inflammation biomarkers MMP-9 and COX-2 is Sirt1-independent. Drug Target Insight. 2012;6:1–11.
23. Salado C, Olaso E, Gallot N, et al. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med. 2011;9:59.
24. Lu X, Kakkar V. Inflammasome and atherogenesis. Curr Pharm Des. 2014;20:108–24.
25. Deng Z, Liu B, Zhou J, et al. Effects of plasma very low density lipoprotein, low density lipoprotein and high density lipoprotein on platelet aggregation in endogenous hypertriglyceridemia. Medical science edition. J Sichuan Univ. 2003;34:704–7.
26. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther. 2002;95:89–100.
27. Vanaja K, Wahl MA, Bukarica L, Heinle H. Liposomes as carriers of the lipid soluble antioxidant resveratrol: evaluation of amelioration of oxidative stress by additional antioxidant vitamin. Life Sci. 2013;93:917–23.
28. Li H, Horke S, Forstermann U. Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci. 2013;34:313–9.
29. Chen M, Nagase M, Fujita T, et al. Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and age. Biochem Biophys Res Commun. 2001;287:962–8.
30. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 2003;10:63–71.
31. Liu X, Qu D, He F, et al. Effect of lycopene on the vascular endothelial function and expression of inflammatory agents in hyperhomocysteinemic rats. Asia Pac J Clin Nutr. 2007;16(Suppl 1):244–8.
32. Sena CM, Nunes E, Louro T, et al. Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats. Br J Pharmacol. 2008;153:894–906.
33. Song R, Li WQ, Dou JL, et al. Resveratrol reduces inflammatory cytokines via inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signal pathway in a rabbit atherosclerosis model. Zhonghua xin xue guan bing za zhi. 2013;41:866–9.
34. Galli M, Van Gool F, Leo O. Sirtuins and inflammation: friends or foes? Biochem Pharmacol. 2011;81:569–76.